Key result
Review outlines small molecule CPT1 regulators for diagnostic and therapeutic applications in diabetes.
Why the study?
Carnitine palmitoyltransferase 1 (CPT1) has been identified as a potential drug target in diabetes, but progress and challenges in CPT-targeted pharmaceuticals remain to be addressed.
This review summarizes the role of carnitine palmitoyltransferase 1 (CPT1) in pathophysiology and the development of CPT1-targeted small molecules for diabetes.
CPT-targeted diabetes therapies remain investigational; leaves open clinical utility pending prospective trials.
This review addresses progress of carnitine palmitoyltransferase targeted pharmaceuticals in diabetes and the challenges ahead. Since the discovery of carnitine palmitoyltransferase (CPT), there are lots of publications on its role in disease. The wide tissue expression, functional and biological roles have documented the physiological importance of these enzymes both in health and disease. Thus, over the years, studies have revealed essential importance of CPT1 in mammalian pathophysiology revealing CPT1 as potential drug targets. Starting from a brief description of the main functional features of CPTs, their roles in physiology and pathophysiology of different human diseases, this review describes the main classes of small molecules which are able to regulate CPT1 for diagnostic and therapeutic applications.
No takes yet. Share an insight, caveat, or question.
CHEN et al. (2016) conducted a review in Diabetes. Carnitine palmitoyltransferase targeted pharmaceuticals was evaluated. This review describes the main classes of small molecules able to regulate carnitine palmitoyltransferase 1 for diagnostic and therapeutic applications in diabetes and other diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: